StockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Stock Down 2.9 %

NASDAQ BLRX opened at $0.29 on Monday. The company has a quick ratio of 1.49, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a fifty-two week low of $0.25 and a fifty-two week high of $1.89. The business has a 50 day moving average price of $0.45 and a two-hundred day moving average price of $0.60. The stock has a market cap of $23.29 million, a PE ratio of -1.30 and a beta of 1.48.

Hedge Funds Weigh In On BioLineRx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Investments Inc increased its holdings in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of BioLineRx in the second quarter valued at $70,000. Finally, CVI Holdings LLC acquired a new stake in BioLineRx during the 2nd quarter worth about $462,000. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.